Introduction
In the UK, one in six couples is faced with the problem of infertility (Cahill and Wardle, 2002) and almost 45 000 cycles of in vitro fertilization (IVF) treatment are carried out annually. In order to compensate for inefficiencies in the process, and to allow for the selection of embryos for intrauterine transfer or cryopreservation, ovarian stimulation is usually performed by administering exogenous gonadotrophins (Macklon et al., 2006) . This approach results in the generation of multiple oocytes from a single treatment cycle, as opposed to the normal menstrual cycle which usually results in the ovulation of a single oocyte (Fauser and Van Heusden, 1997) .
For ovarian stimulation, recombinant follicle-stimulating hormone (recFSH) preparations are currently administered in dosages ranging from 100 to 600 IU/day (Nargund et al., 2007; Malizia et al., 2009) . The induced multiple follicular development carries the risk of premature luteinization. Co-treatment with gonadotrophin-releasing hormone (GnRH) agonist or antagonist is normally instituted to prevent an untimely rise in the luteinizing hormone (LH) (Huirne and Lambalk, 2001) . The costs of the gonadotrophins represent a significant proportion (up to 30%) of the costs for an entire IVF treatment cycle (Wechowski et al., 2009) . Therefore, a reduction in the amount of recFSH-administered would significantly affect the costs of an IVF treatment.
At present, the optimal starting dose for ovarian stimulation leading to the highest possibility of achieving a pregnancy, while minimizing the chances for major patient discomfort and complications, is not known. Studies reporting the dose-effect relationship for this type of medication are scarce, and current practice is largely based on empirical considerations. The aim of the current systemic review is to identify the optimal daily starting dose of recFSH taking into account ovarian response, pregnancy chances, rate of cycle cancellation and the incidence of the potentially life-threatening complication of ovarian hyperstimulation syndrome (OHSS). Published randomized comparative dosage trials were searched in order to identify the recFSH dose with the best clinical efficacy, cost-effectiveness and safety profile.
Methods

Search strategy, selection criteria and data collection
In this meta-analysis, the Quality of Reporting of Meta-analyses (QUOROM) guidelines were adhered to. Prior to performance of the literature search, a number of inclusion criteria were established. Only randomized controlled trials were considered eligible. The reported methods of allocation concealment were critically assessed: (i) allocation was adequate, (ii) allocation was unclear and (iii) allocation was inadequate. In order to be included, it was necessary that the trials compared different starting dosages of recFSH for ovarian stimulation in women aged between 18 and 40 years undergoing IVF/ICSI treatment. We performed an electronic search of MEDLINE and EMBASE for English and non-English language publications from 1984 until October 2009. The following Medical Subject Headings (MeSH) search terms were used: 'IVF', 'ICSI', 'ART', 'ovarian stimulation', 'recFSH', 'gonadotrophin' and 'RCT'.
The MeSH strategy yielded 2404 publications in MEDLINE, EMBASE and the Cochrane library. Of those publications, 2356 (including duplicates) were excluded because it was clear from the title that they did not fulfil the selection criteria. From the remaining 48 articles, 25 could be excluded on the basis of the abstracts. Two reviewers (M.D.S. and S.M.V.-V.) independently reviewed the remaining 23 articles and extracted data from each study using a standardized form. Discrepancies were resolved by discussion and consensus. Finally, the bibliographies of identified studies were hand searched. Figure 1 summarizes the flowchart of article selection and inclusion. When clarification was required regarding an individual study, the first or senior author of the respective article was contacted. The parameter was stated not estimable if no further information could be obtained.
Statistical analysis
Since most of the studies compared either a dose of 100 IU/day versus higher, or 150 IU/day versus higher, two comparisons were made. Comparison A addressed 100 IU/day recFSH versus 200 IU/day recFSH, and comparison B 150 versus 200 -250 IU/day recFSH. Further pooling of these groups was considered inappropriate since there was an overlap in dose (a high dose in one study could be the lower dose in another study).
When the outcome of interest was a continuous variable (e.g. number of oocytes), the difference in mean value between the two groups was calculated together with the standard error. These differences were pooled across studies, resulting in a weighted mean difference (WMD). Pooling was performed using the inverse of the variance as weight. For dichotomous outcome parameters (e.g. cancellation), the odds ratios (ORs) per study were calculated and pooled. Pooling was performed using the Mantel-Haenszel method. Statistical pooling was performed for the following outcome parameters: number of oocytes retrieved, clinical pregnancy rate, cancellation rate due to low response, amount of gonadotrophins in IU, OHSS rate and number of cryopreserved embryos.
The 95% confidence intervals (CIs) were calculated for the WMD and pooled ORs, respectively, using the random effects method. The random effect method is preferred because it remains valid even if true heterogeneity between studies is present, therefore we will only present random effects estimates. Statistical heterogeneity between studies was tested for all the outcome parameters and quantified by the I 2 statistic. This describes the percentage of the variability in the effect estimates that is due to heterogeneity rather than sampling variation. A value .50% is considered as moderate/high heterogeneity (Higgins et al., 2003) . In case of statistically significant heterogeneity, univariate meta-regression was performed using the random effects method described by van Houwelingen et al. (2002) , on the following study characteristics: mean age, mean BMI, duration of infertility, percentage of primary infertility and use of a GnRH analogue. All parameters were reported per started cycle, except for the number of oocytes which were calculated per ovum pick up and the number of frozen embryos which were stated per embryo transfer. All analyses were performed in Review Manager 5.
Results
We identified 11 relevant dosage RCTs reporting data on 1967 women undergoing a single IVF cycle. All trials had parallel design and in most studies the treatment was adequately concealed prior to allocation eight studies allocation score A (Out et al., 1999 (Out et al., , 2000 (Out et al., , 2001 (Out et al., , 2004 Latin-American Puregon IVF Study Group, 2001; Wikland et al., 2001; Hoomans et al., 2002; Tan et al., 2005) ) six studies met the criteria for inclusion in the analysis. Unfortunately, as it was the only study eligible for comparison A which compared 100 versus 150 IU/day and used the GnRH antagonist as co-treatment, we had to exclude one pilot study (de Jong et al., 2000) because of the small numbers of patients (15 in total). Therefore, comparison A involved 960 women in total. The remaining five studies were analyzed in comparison B (150 versus 200 -250 IU/day recFSH), involving 992 women. Table I summarizes the inclusion and exclusion criteria per included RCT. All the RCTs included presumed normal responders in their studies (age younger than 39 year, normal basal FSH, regular menstrual cycle and two normal ovaries). Table II summarizes the characteristics of the included studies and the participants. In all studies the upper limit of included ages was at least 35 years.
The main outcome parameters are summarized in Figs 2-7. Figure 2 shows the number of oocytes obtained per oocyte retrieval. In comparison A, the 100 IU/day recFSH group yielded significantly fewer oocytes compared with the higher dose group (mean difference 23.56; 95% CI 24.86, 22.27; P , 0.0001). In comparison B, the 150 IU/day recFSH users obtained 1.7 oocytes fewer than those applying higher dosages (mean difference 21.67; 95% CI 22.53, 20.81; P ¼ 0.0001).
In comparison A, the higher dose group obtained more cryopreserved embryos per embryo transfer (mean difference 1.40; 95% CI 22.32, 20.47; P ¼ 0.003). No difference as observed for comparison B in the number of frozen embryos obtained (mean difference 20.05; 95% CI 20.49, -0.39; P ¼ 0.82) (Fig. 3) . Figure 4 demonstrates the difference in the total amount of recFSH administered between the lower and the higher dose groups. The mean difference in both comparisons is very similar, but the CI differs (comparison A: mean difference 2813.72 IU/day; 95% CI 2860.26, 2767.17; P , 0.0001 comparison B: mean difference 2671.98 IU/day; 95% CI 2896.85, 2447.10; P , 0.0001).
In both comparison groups A and B, the pregnancy rates per started IVF/ICSI cycle did not differ between lower and higher dosages [comparison A: OR 0.95 (calculated pooled estimates 19.5 and 20.3%, respectively), 95% CI 0.69 -1.30, P ¼ 0.74; comparison B: OR 1.14 calculated pooled estimates 26.8 and 24.2%, respectively; 95% CI 0.85 -1.51, P ¼ 0.38] (Fig. 5) .
Cancellation due to low ovarian response to stimulation in comparison A (Fig. 6 ) was observed to be more frequent in the 100 IU/day recFSH dose group [OR 5.02 (calculated pooled estimates 16.4 and 3.8%, respectively); 95% CI 2.19 -11.51; P ¼ 0.0001]. There was no difference in cancellation rate for low response in comparison B [OR 1.10 (calculated pooled estimates 4.4 and 4.0%, respectively); 95% CI 0.59 -2.05; P ¼ 0.76]. Figure 7 illustrates the risk of OHSS in relation to dose. In comparison A, the risk was reduced in the 100 IU/day recFSH dosage dose group by a factor of almost two [OR 0.58 (calculated pooled estimates 1.9 and 3.4%, respectively); 95% CI 0.18-1.90; P ¼ 0.37]. In comparison B, the risk for OHSS was 33% lower in the 150 IU/day recFSH group compared with the higher dosage group [OR 0.67 (calculated pooled estimates 2.6 and 3.8%, respectively); 95% CI 0.33 -1.37; P ¼ 0.27]. However, for both comparison groups these ORs were not significantly different.
Heterogeneity across comparisons was found for the parameters number of oocytes (comparison A I 2 ¼ 65%), number of frozen embryos (comparison A I 2 ¼ 80%) and total amount of recFSH (com-
In meta-regression on the parameter number of oocytes, none of the study characteristics explained the heterogeneity. For the parameter number of frozen embryos, the body mass index (BMI) was the characteristic which could explain this heterogeneity. Women with a lower BMI showed a greater dose-related difference in the number of embryos available for freezing, and this was similarly evident in both the comparison groups. In comparison B, heterogeneity in the total amount of recFSH was explained by the study characteristic age. The first two studies (Out et al., 2000; Latin-American Puregon IVF Study Group, 2001 ) have a mean age around 35 years and the rest of the studies (Wikland et al., 2001; Out et al., 2004; Cavagna et al., 2006) , around 32 years. The studies with the 'older' patients have a larger difference in total amount of recFSH (Fig. 4) .
Discussion
Until now, no consensus regarding the optimal starting dose of FSH for ovarian hyperstimulation in IVF/ICSI treatment cycles in presumed normal responders exists. Sufficiently powered dose -response studies providing useful information in relation to the preferred effective starting dose of exogenous gonadotrophins are scarce. Despite this lack of information, many clinicians have strong beliefs as to what constitutes the best dose regimen for their patients. However, this is based largely on personal experience and limited empirical research. Therefore, practices vary throughout the world and even between IVF centers within the same country. These differences in patient management may have major implications for IVF pregnancy rates, drug costs, complication rates and possibly also for patient discomfort.
The current meta-analysis represents a first attempt to provide objective information regarding the relationship between the applied daily FSH dose for ovarian stimulation in presumed normal responders in IVF/ICSI and the outcomes, cost and complications of the treatment. This study demonstrates that the average number of oocytes retrieved per pick-up is increased when higher FSH doses over 100 IU/day are given, whereas pregnancy rates do not differ across the dosage range tested (Fig. 8) . Moreover, the number of frozen embryos available for subsequent transfer does not improve with dosages exceeding 150 IU/day, suggesting that cumulative pregnancy rates (including additional cryo embryo transfer cycles) will not become superior.
Pharmacodynamic studies of recFSH have shown that the response to a 225 IU daily dose varies mainly according to the women's age and her ovarian reserve status (Karlsson et al., 1997) . This finding implies that a limitation exists under given circumstances in the number of follicles that can be stimulated to ongoing development. The comparison between 150 IU/day and higher dosages revealed that the increase in number of oocytes harvested is limited. This may indicate that the dose eliciting optimal stimulation of the ovaries in most patients may be somewhere between 150 and 200 IU/day. Using a dosage of 100 IU/day leads to a more pronounced reduction in oocyte number compared with higher doses, suggesting that in this dose range a dose-response relationship does exist. With current starting dosages of 150 IU/day or more in most centers, optimal or near optimal stimulation of the ovaries will usually be obtained.
In recent years, so-called 'mild' stimulation regimens have been proposed, aimed at harvesting more modest numbers of oocytes (Nargund et al., 2007 are associated with medical, health, economic and psychological benefits (Heijnen et al., 2007) . The present meta-analysis demonstrates that even in conventional GnRH agonist stimulation regimes the use of lower daily dosages of recFSH (i.e. 100 IU/day) produces more modest ovarian responses without undesirable effects on pregnancy rates. Consistent with these findings, a recent study in which recFSH dose adaptations were based on individualized patient profiles, ranging from 75 up to 225 IU/day, revealed that in 30% of patients, a dose of 100 IU/day or less is sufficient to obtain moderate oocyte numbers with high pregnancy rates (Olivennes et al., 2009) . Milder ovarian responses may create equal numbers of good quality embryos compared with conventional stimulation approaches (Hohmann et al., 2003; Baart et al., 2007) . The current paradigm of a standard dose which will work for the majority of women is therefore being increasingly questioned (Fauser et al., 2008) . In the current meta-analysis, data were pooled in two comparison groups (A: 100 A potentially negative outcome of giving a lower dose of recFSH is the risk of low response resulting in cycle cancellation. However, we have previously shown in this meta-analysis that the pregnancy rates following low dosage use are similar to conventional dosages. This indicates that doctors should not be unduly concerned if a low response is observed and can proceed to aspiration of the oocytes even when few follicles are present. When using 150 IU/day the probability of low response is not different from higher dosages, indicating that in general, 150 IU/day is likely to represent the optimal dosage.
Extreme responses to ovarian stimulation introduce the risk of developing the OHSS (Delvigne and Rozenberg, 2002; Aboulghar and Mansour, 2003) . Although early diagnosis and treatment may minimize the risk of catastrophic events (such as thromboembolism and multiple organ failure) preventing the occurrence of OHSS remains the cornerstone of proper management. Alongside refraining from human chorionic gonadotrophin for triggering of final oocyte maturation or the cryopreservation of all embryos obtained in very high responder patients, avoiding extreme ovarian response should Clinical outcomes and daily FSH dose IVF be regarded as the primary approach in the prevention of OHSS. The tendency for lower OHSS rates in lower dose groups, as demonstrated in the present meta-analysis, further supports the approach of submaximal ovarian stimulation.
Reduction in total recFSH dose would also considerably cut the cost of IVF treatment. As the total duration of stimulation (on average 12 days) is not affected by dosage changes, the use of a standard dose of 150 IU/day, instead of 225 IU/day, would reduce per-cycle costs of gonadotrophin medication by 30% (Wechowski et al., 2009 ). This would imply that every set of two IVF treatment cycles will save the amount of recFSH sufficient for a third stimulation cycle. The use of GnRH antagonist as co-treatment might lead to an even lower consumption of recFSH, mainly by a reduction in the duration of stimulation due to relatively high endogenous FSH concentrations early during the stimulation cycle (Fauser and Van Heusden, 1997; Baart et al., 2007; Heijnen et al., 2007) .
Significant strengths of the current meta-analysis are that it was performed according to the QUOROM guidelines, that almost 2000 IVF cycles were involved in the analysis, that heterogeneity was addressed and was explained by meta-regression. We had to split the dosage comparisons into two groups. An advantage of this split was that we could assess the dose at which there was no more gain of a higher dose and thus determine the optimal starting dose. Limitations of this study are that the patient groups were more restricted in age and BMI than is seen in everyday practice. Furthermore, the most relevant clinical end-point, cumulative live birth, was not available in most studies. We therefore had to restrict the analysis to ongoing pregnancy rates. The effect of OHSS is overestimated since in some studies no distinction was made between mild, moderate and severe OHSS. Another limitation of this meta-analysis is that all included studies had the number of oocytes as primary outcome parameter. Therefore none of the studies were powered for differences in pregnancy rates. The pooling of data, however, has allowed for drawing valid conclusions on the effect of FSH dosage level on the clinical pregnancy rates. Finally, all underlying studies applied a so-called 'one-size fits all' approach, with no possibilities for patient- tailored adjustments based on individual patient characteristics (Popovic-Todorovic et al., 2003b) .
In conclusion, this meta-analysis suggests that the optimal starting dose of recFSH for IVF/ICSI is 150 IU daily in presumed normal responders younger than 39 years. This dose is associated with a more modest oocyte yield, but an equal pregnancy rate compared with higher doses. Further benefits of this dose include a possible reduction in the risk for OHSS, in the face of sufficient numbers of oocytes to allow for cryopreservation of surplus embryos. In the future, the use of patient-tailored approaches may further optimize the risk-benefit balance, increasing the proportion of women exhibiting an adequate ovarian response while further reducing the need for intense monitoring of ovarian response (Popovic-Todorovic et al., 2003a; Fauser et al., 2008; Olivennes et al., 2009) .
